Nicole L Mihalopoulos1, Jeffrey T Yap2,3, Britney Beardmore2, Richard Holubkov4, M Nazeem Nanjee5, John M Hoffman2,3. 1. Division of Adolescent Medicine, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA. 2. Center for Quantitative Cancer Imaging, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA. 3. Department of Radiology and Imaging Science, University of Utah, Salt Lake City, Utah, USA. 4. Division of Critical Care Medicine, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA. 5. Department of Cardiovascular Genetics, University of Utah, Salt Lake City, Utah, USA.
Abstract
OBJECTIVE: This study aimed to test the hypothesis that young adults with obesity and cold-activated brown adipose tissue (BAT) are less likely to have metabolic dysfunction (dyslipidemia, insulin resistance, and hypertension) than those without cold-activated BAT. Previous studies have noted a potentially protective effect of BAT and higher adiponectin/leptin ratios, but they have acknowledged that the clinical implications of these findings remain uncertain. METHODS: Twenty-one females and twenty-three males with obesity (BMI ≥ 30 kg/m2 ) underwent a 2-hour cooling protocol before 18 F-fluorodeoxyglucose (18 F-FDG)-positron emission tomography/x-ray computed tomography scan to determine the prevalence, volume, and 18 F-FDG uptake of cold-activated BAT. RESULTS: Cold-activated BAT was identified in 43% of participants (11 female, 8 male); females had greater 18 F-FDG uptake. Those with cold-activated BAT had a lesser degree of metabolic dysfunction. Cold-activated BAT volume correlated with triglycerides (inversely) and adiponectin (concordantly). Body-mass-adjusted cold-activated BAT activity correlated with high-density lipoprotein cholesterol (concordantly). Males with cold-activated BAT had lower leptin and higher adiponectin/leptin ratio. CONCLUSIONS: A high prevalence of cold-activated BAT was found in the study participants. BAT could be important in decreasing metabolic dysfunction among young adults with obesity, making it a potential target for treating metabolically unhealthy obesity.
OBJECTIVE: This study aimed to test the hypothesis that young adults with obesity and cold-activated brown adipose tissue (BAT) are less likely to have metabolic dysfunction (dyslipidemia, insulin resistance, and hypertension) than those without cold-activated BAT. Previous studies have noted a potentially protective effect of BAT and higher adiponectin/leptin ratios, but they have acknowledged that the clinical implications of these findings remain uncertain. METHODS: Twenty-one females and twenty-three males with obesity (BMI ≥ 30 kg/m2 ) underwent a 2-hour cooling protocol before 18 F-fluorodeoxyglucose (18 F-FDG)-positron emission tomography/x-ray computed tomography scan to determine the prevalence, volume, and 18 F-FDG uptake of cold-activated BAT. RESULTS: Cold-activated BAT was identified in 43% of participants (11 female, 8 male); females had greater 18 F-FDG uptake. Those with cold-activated BAT had a lesser degree of metabolic dysfunction. Cold-activated BAT volume correlated with triglycerides (inversely) and adiponectin (concordantly). Body-mass-adjusted cold-activated BAT activity correlated with high-density lipoprotein cholesterol (concordantly). Males with cold-activated BAT had lower leptin and higher adiponectin/leptin ratio. CONCLUSIONS: A high prevalence of cold-activated BAT was found in the study participants. BAT could be important in decreasing metabolic dysfunction among young adults with obesity, making it a potential target for treating metabolically unhealthy obesity.
Authors: K Selthofer-Relatić; R Radić; A Stupin; V Šišljagić; I Bošnjak; N Bulj; R Selthofer; D Delić Brkljačić Journal: Diab Vasc Dis Res Date: 2018-01-10 Impact factor: 3.291
Authors: Steve C N Hui; Jacky K L Ko; Teng Zhang; Lin Shi; David K W Yeung; Defeng Wang; Queenie Chan; Winnie C W Chu Journal: J Magn Reson Imaging Date: 2017-01-16 Impact factor: 4.813
Authors: Denis P Blondin; Sébastien M Labbé; Christophe Noll; Margaret Kunach; Serge Phoenix; Brigitte Guérin; Éric E Turcotte; François Haman; Denis Richard; André C Carpentier Journal: Diabetes Date: 2015-02-12 Impact factor: 9.461
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Anouk A J J van der Lans; Roel Wierts; Maarten J Vosselman; Patrick Schrauwen; Boudewijn Brans; Wouter D van Marken Lichtenbelt Journal: Am J Physiol Regul Integr Comp Physiol Date: 2014-07-15 Impact factor: 3.619
Authors: Guy H E J Vijgen; Nicole D Bouvy; G J Jaap Teule; Boudewijn Brans; Patrick Schrauwen; Wouter D van Marken Lichtenbelt Journal: PLoS One Date: 2011-02-24 Impact factor: 3.240
Authors: Maria Chondronikola; Elena Volpi; Elisabet Børsheim; Craig Porter; Palam Annamalai; Sven Enerbäck; Martin E Lidell; Manish K Saraf; Sebastien M Labbe; Nicholas M Hurren; Christina Yfanti; Tony Chao; Clark R Andersen; Fernando Cesani; Hal Hawkins; Labros S Sidossis Journal: Diabetes Date: 2014-07-23 Impact factor: 9.461
Authors: Oana C Kulterer; Carsten T Herz; Marlene Prager; Christoph Schmöltzer; Felix B Langer; Gerhard Prager; Rodrig Marculescu; Alexandra Kautzky-Willer; Marcus Hacker; Alexander R Haug; Florian W Kiefer Journal: Front Endocrinol (Lausanne) Date: 2022-03-31 Impact factor: 6.055
Authors: Milena Monfort-Pires; Giulianna Regeni-Silva; Prince Dadson; Guilherme A Nogueira; Mueez U-Din; Sandra R G Ferreira; Marcelo Tatit Sapienza; Kirsi A Virtanen; Licio A Velloso Journal: Front Endocrinol (Lausanne) Date: 2022-07-19 Impact factor: 6.055